Navigation Links
Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes
Date:12/11/2009

ARDEE, Ireland, Dec. 11 /PRNewswire-FirstCall/ -- As Warner Chilcott plc (Nasdaq: WCRX) has previously disclosed, its acquisition of the global branded prescription pharmaceuticals business of The Procter & Gamble Company ("P&G") on October 30, 2009 (the "PGP Acquisition"), constituted a change of control under a global marketing and collaboration agreement (the "Marketing Agreement") between a P&G subsidiary acquired by Warner Chilcott and Sanofi-Aventis U.S. LLC ("Sanofi") relating to the development and sale of risedronate products (including Actonel®). Pursuant to the Marketing Agreement, the change of control gives Sanofi the right to exercise an option to put its interest in the Marketing Agreement to Warner Chilcott at a fair market value to be determined by independent third party firms (the "Sanofi Put"). In conjunction with the closing of the PGP Acquisition, certain subsidiaries of the Company entered into senior secured credit facilities (the "Senior Secured Facilities"), which included a delayed-draw term loan facility in the amount of $350.0 million to be borrowed, if necessary, to discharge, in whole or in part, the obligations of the Company or its subsidiaries in connection with the exercise of the Sanofi Put.

In the event that Sanofi does not exercise the Sanofi Put, the Company is seeking an amendment to the Senior Secured Facilities that would allow the Company and its subsidiaries to use proceeds borrowed under the delayed-draw term loan facility or a new facility to repurchase or redeem its outstanding 8.75% Senior Subordinated Notes due 2015 (the "Notes"). The Company can offer no assurance that the Sanofi Put will not be exercised, that the Company will obtain an amendment to the Senior Secured Facilities or that the Company will elect to repurchase or redeem the Notes.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the U.S. and Western European pharmaceuticals markets. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G.

Read more on www.wcrx.com.

Forward Looking Statements:

This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and our Current Report on Form 8-K filed on November 2, 2009; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.

SOURCE Warner Chilcott plc


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Prices Secondary Equity Offering
2. Warner Chilcott Announces Secondary Equity Offering
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
5. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
8. Drug Candidates in Pipeline Offer Potential for Parkinsons Disease Therapeutics Market, Says Frost & Sullivan
9. Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
10. Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
11. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Product Type and by Application - Global Opportunity Analysis and Industry ... in 2015, and is expected to reach $5,255 million by 2022, growing at ... market in 2015 with more than four-fifths share. ... ...
(Date:12/5/2016)... Dec. 5, 2016  Wellbridge Health and Gateway Health proudly ... solutions to Medicare and Medicaid plan members with specific high ... the unique needs of this group of consumers, Wellbridge combines ... philosophies to provide insight into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... For the third consecutive year, Astellas has ... Rights Campaign Foundation,s (HRC) annual Corporate Equality ... tool used to rate companies on policies and practices ... For the last 15 years, HRC has ... equality efforts, culture and business practices. The survey rates ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... ... the 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and ... Talamo said, “We are honored to have Amy E. Herman present at this ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one of New ... recently participated in the 36th Annual Cutting Edge Aesthetic Symposium at the Waldorf Astoria ... getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for his expertise ...
(Date:12/5/2016)... MALVERN, PA (PRWEB) , ... ... ... Management ("CSM"), a Great Point Partners ("GPP") portfolio company, today announced it ... Clinical Supplies ("TCS"). TCS was previously a subsidiary of Chiltern International ...
(Date:12/5/2016)... ... ... Shah MD, MBA has joined the Retina Group of New York (RGONY) specializing ... M. Maisel, MD and has been providing tertiary medical and surgical retinal care on Long ... expectations amongst her peers. Growing up in a family of doctors, Dr. Shah emulated ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
Breaking Medicine News(10 mins):